DORAVIRINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H11ClF3N5O3
Molecular Weight	425.749
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C(=O)NN=C1CN2C=CC(=C(OC3=CC(Cl)=CC(=C3)C#N)C2=O)C(F)(F)F

InChI

InChIKey=ZIAOVIPSKUPPQW-UHFFFAOYSA-N

InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)

HIDE SMILES / InChI

Molecular Formula	C17H11ClF3N5O3
Molecular Weight	425.749
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24379202 | http://adisinsight.springer.com/drugs/800035289 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000,210807Orig1s000Lbl.pdf | https://aidsinfo.nih.gov/drugs/546/doravirine/0/patient

Doravirine (MK-1439) is a nonnucleoside inhibitor of HIV reverse transcriptase (NNRTI). It displays excellent activities against not only WT viruses but also a broader panel of NNRTI-resistant viruses. Doravirine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults who have never taken HIV medicines before. Doravirine is always used in combination with other HIV medicines.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 70 Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24379202	Inhibitor 8504		12.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: https://aidsinfo.nih.gov/drugs/546/doravirine/0/patient https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000,210807Orig1s000Lbl.pdf	Primary		Approved 8583	PIFELTRO Approved Use PIFELTRO, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history. (1) Launch Date 2018

C_max

Value	Dose	Co-administered	Analyte	Population
0.962 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DORAVIRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
16.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DORAVIRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
15 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DORAVIRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
24% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DORAVIRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29592840/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29592840/	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/29592840/
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	Other AEs: Nausea, Headache... Other AEs: Nausea (all grades, 7%) Headache (all grades, 6%) Fatigue (all grades, 6%) Diarrhea (all grades, 5%) Abdominal pain (all grades, 5%) Dizziness (all grades, 3%) Rash (all grades, 2%) Abnormal dreams (all grades, 1%) Insomnia (all grades, 1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	Other AEs: Bilirubin total increased, Creatinine increased... Other AEs: Bilirubin total increased (5%) Creatinine increased (2%) Aspartate aminotransferase increase (4%) Lipase increased (7%) Creatine kinase increased (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA009CJK	https://www.aablocks.com/goods/Goods/detail?id=AA009CJK
abcr GmbH	AB512636	http://www.abcr.com/shop/en/AB512636
Acadechem	ACDS-0781673	http://acadechemical.com/product/229219
Adooq BioScience	A12443	https://www.adooq.com/mk-1439.html
Alichem	29200191	http://www.alichem.com/en/products/1338225-97-0.html
Allbio Pharm Co., Ltd	AF16798	http://www.allbiopharm.com/product/n/AF16798
Alsachim	4668	http://www.alsachim.com/product-C6016-glo.bal-view.html
Angel Pharmatech	AG-11429	http://www.angelpharmatech.com/1338225-97-0.html
Ark Pharma Scientific Limited	A-1382	http://www.arkpharmtech.com/product/33333.html
Ark Pharma Scientific Limited	A-1852	http://www.arkpharmtech.com/product/274044.html
BioChemPartner	BCP02296	http://www.biochempartner.com/1338225-97-0-BCP02296
BOC Sciences	1338225-97-0	https://www.bocsci.com/doravirine-cas-1338225-97-0-item-475314.html
Chem Scene	CS-5924	http://www.chemscene.com/1338225-97-0.html
Chemspace	CSSB00025757702	https://chem-space.com/CSSB00025757702
DC Chemicals	DC9308	http://www.dcchemicals.com/product_show-Doravirine_MK_1439_.html
Debye Scientific	DB-091410	http://www.debyesci.com/cas_1338225-97-0.html
eNovation Chemicals	D570915	https://www.enovationchem.com/ProductDetails.asp?ProductID=D570915
eNovation Chemicals	Y0975591	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975591
Excenen	EX-A1968	https://www.excenen.com/searchresultlist.php?id=1338225-97-0
Hefei Hirisun Pharmatech Co., Ltd	HR141299	http://hirisunpharm.com/1338225-97-0.html
Lab Network	LN01344091	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01344091
MedChem Express	HY-16767	https://www.medchemexpress.com/Doravirine.html
Smolecule	S526526	http://www.smolecule.com/products/s526526
Sun-shine Chemical	Doravirine	http://www.sun-shinechem.com/Details/Doravirine/2009/1338225-97-0.html
Synblock Inc	SB17104	http://www.synblock.com/product/1338225-97-0.html
THE BioTek	bt-266308	https://www.thebiotek.com/product/inhibitors/bt-266308

PubMed

Title	Date	PubMed
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.	2014-02-01	24412110
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.	2014	24379202

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dosage: One tablet taken orally once daily with or without food in adult patients. (2.1) Dosage adjustment with rifabutin: One tablet taken twice daily (approximately 12 hours apart). (2.2) Tablets: 100 mg doravirine.

Route of Administration: Oral

In Vitro Use Guide

In the presence of 50% normal human serum (NHS), Doravirine (MK-1439) showed excellent potency in suppressing the replication of WT HIV-1 virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC95 of 43, 27, and 55 nM, respectively. MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:49:54 GMT 2025` Edited by `admin` on `Wed Apr 02 09:49:54 GMT 2025`
Record UNII	913P6LK81M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DORAVIRINE

Official Name

English

DELSTRIGO COMPONENT DORAVIRINE

Preferred Name

English

DORAVIRINE [MI]

Common Name

English

DORAVIRINE [USAN]

Common Name

English

3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile

Systematic Name

English

BENZONITRILE, 3-CHLORO-5-((1-((4,5-DIHYDRO-4-METHYL-5-OXO-1H-1,2,4-TRIAZOL-3-YL)METHYL)-1,2-DIHYDRO-2-OXO-4-(TRIFLUOROMETHYL)-3-PYRIDINYL)OXY)-

Systematic Name

English

PIFELTRO

Brand Name

English

DORAVIRINE [JAN]

Common Name

English

MK-1439A

Brand Name

English

Doravirine [WHO-DD]

Common Name

English

MK-1439

Brand Name

English

doravirine [INN]

Common Name

English

DORAVIRINE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

WHO-ATC

J05AG06